전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved14 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleElevation OncologyPhase 1

CYRAMZA® (Ramucirumab, Ramucirumab (CYRAMZA®))

Stomach Neoplasm; Gastrointestinal Neoplasms · Stomach Neoplasm

#StomachNeoplasm#Antibody#Phase1#Popular#monoclonal-antibody+3
Trials 84Status Discontinued
AntibodyLimited DatastaleAlliance for Clinical Trials in…Phase 2

Epratuzumab (Epratuzumab)

Lymphoma · Leukemia

#Leukemia#Antibody#Phase2#monoclonal-antibody#Lymphoma+1
Trials 30Status Discontinued
AntibodyLimited DatastaleALX Oncology Inc.Phase 2

ALX148 (Evorpacept, Evorpacept (ALX148))

Breast Cancer, Metastatic · Breast Cancer, Metastatic

#BreastCancerMetastatic#Antibody#Phase2#monoclonal-antibody#BreastCancer+2
Trials 15Status Recruiting
ADCLimited DatastaleALX Oncology Inc.Phase 2

Evorpacept (Evorpacept)

Plasma Cell Myeloma Refractory · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#PlasmaCellMyelomaRefractory+1
Trials 14Status Recruiting
CGTLimited DatastaleTaiho Oncology, Inc.Phase 2

ASTX660 (ASTX660)

Solid Tumors; Lymphoma · Solid Tumors

#SolidTumors#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 11Status Recruiting
CGTLimited DatastaleCG Oncology, Inc.Phase 2

oncolytic adenovirus expressing GMCSF (oncolytic adenovirus expressing GMCSF)

Bladder Cancer; High Grade · Bladder Cancer

#BladderCancer#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 2Status Discontinued
AntibodyLimited DatastaleSouth Eastern European Research…Phase 2

Capecitabine and Bevacizumab (Capecitabine and Bevacizumab)

Breast Cancer; Metastasis · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Metastasis+1
Trials 1Status Active
CGTLimited DatastaleChildren's Oncology GroupPhase 1

HER2 Specific CAR T Cell (HER2 Specific CAR T Cell)

Ependymoma · HER2

#HER2#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 + nivolumab)

Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#HeadandNeckCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 and nivolumab)

Urothelial Carcinoma; Urothelial Carcinoma Bladder · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase1#monoclonal-antibody#UrothelialCarcinomaBladder+1
Trials 1Status Active
AntibodyLimited DatastaleBristol-Myers SquibbPreclinical

nivolumab (Opdivo, Immuno-oncology-based therapy, excluding nivolumab-based regimens, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy)

Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer (NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Preclinical#monoclonal-antibody#Bristol-Myers
Trials 1Status Recruiting
CGTLimited DatastaleCelyad Oncology SAPhase 1

NKR-2 CAR-T Cells (NKR-2 CAR-T Cells)

AML, Adult; Myelodysplastic Syndromes · AML, Adult

#AMLAdult#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Discontinued
CGTLimited DatastaleShanghai Gynecologic Oncology G…Phase 1

SCT-001 CAR-T cells (SCT-001 CAR-T cells)

Ovarian Cancer; Fallopian Tube Carcinoma · Ovarian Cancer

#OvarianCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleElevation OncologyPhase 2

Seribantumab (Seribantumab)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase2#monoclonal-antibody#Elevation
Trials 1Status Discontinued